Clinical data on other diseases

Hepatitis B

Female in the 60s
Chief Complaint: No significant symptoms
Past Medical History: Depression

Current Medical History:
She had received treatment for hepatitis B at another hospital for about 20 years. She had been intravenously given 5 ampoules of conservative treatment of liver sick drug (SMC) four days a week, however no improvement had been observed. She visited our clinic in August 2002. After the informed consent procedure, she began taking fucoidan mix as a treatment option without impairing the QOL.

Treatment outcomes:
After taking 1.0g of fucoidan mix per day, her levels of GOT were reduced to 9450, and her GPT levels were reduced to 79 from 36. She had received 5 ampoules of liver asylum agent (SMC) (intravenous injection) at the previous hospital. During the treatment at our hospital, the agent was reduced to 1 ampoule from 3 ampoules, then administration of SMC became no longer necessary 6 months later.

※Data taken over the period of treatment

【Biochemistry tests】
Fucoidan mix intake per day: Approximately 1.0g

May 2002 August 2002 October 2002 March 2003 June 2004
GOT
(10〜40)
107 94 79 45 50 (IU/l)
GPT
(5〜40)
115 79 66 37 36 (IU/l)

SMC 5A→3A→1A→off(Half a year later)

Hepatitis C

Female in the 60s
Chief Complaint: No significant symptoms
Past Medical History: Angina pectoris

Current Medical History:
She had received treatment for hepatitis C at another hospital. She visited our clinic in March 2003. After the informed consent procedure, she began treatment with fucoidan mix.

Treatment outcomes:
After taking approximately 1g of fucoidan mix per day, her levels of AFP were decreased to 12.0 from 33.4 in approximately 2 months.

※Data taken over the period of treatment

【Tumor markers】

March 2003 May 2003 November 2004
AFP (< 10.0) 33.4 23.6 12.0 (ng/ml)

Intractable duodenal ulcer

Female in the 80s
Chief Complaint: Abdominal pain
Medical History: intractable duodenal ulcer, rheumatoid arthritis and angina pectoris

Current Medical history:
She received helicobacter pylori eradication and PPI therapy, to combat the duodenal ulcer in May 2002 which then improved. Then, in August the same year, it relapsed. Again, she received H. pylori eradication treatment and PPI therapy. However, there were no signs of improvement this time. This was the time when we proposed the administration of fucoidan mix. After providing sufficient information on fucoidan, she and her family members agreed and she began receiving fucoidan mix treatment. Her condition improved dramatically enough to be discharged from hospital. Thereafter, we continued prescribing fucoidan mix and PPI. She visited our hospital complaining of abdominal pain in June 2003. The examination result showed that the duodenal ulcer had relapsed. After interviewing the patient, it was found that she had made her own judgement and discontinued taking fucoidan mix since April 2003. She had continued only the PPI. So, we started the administration of fucoidan mix again.

Treatment outcomes:
When her duodenal ulcer was found to have relapsed, she was provided with fucoidan mix. In one week, the ulcer improved.

※Data taken over the period of treatment

《Endoscope of the duodenal ulcer area》
Fucoidan mix intake per day: Approximately 2.5g

other_01
June 2003 Recurrence of Duodenal ulcer
other_02
June 2003, one week after the discovery of duodenal ulcer recurrence

Intractable gastric ulcer

Female in the 60s
Chief Complaint: Epigastric pain
Past Medical History: Gastric ulcer

Current Medical History:
She had been administered PPI, but gastric ulcer had continued recurring over several years, which developed into intractable gastric ulcer. In April 2013 she began fucoidan treatment.

Treatment outcomes:
Intractable gastric ulcer was improved in about four months after the initiation of the combination treatment of fucoidan and PPI.
※Data taken over the period of treatment

《Endoscopy of the upper gastrointestinal tract》
Daily dosage of fucoidan mix in April 2013 ~ 1.25g
Daily dosage of fucoidan mix in June 2013 ~ 0.75g

other_03
April 2013
other_04
August 2013



Fucoidan mix・・・It is composed of mozuku extracted fucoidan, mekabu extracted fucoidan and agaricus mycelium.

Today, active research is conducted on fucoidan and various bioactive functions of fucoidan, such as “anti-cancer action,” “cholesterol-lowering action,” “blood-pressure lowering action” and “anti-virus action,” have been revealed.

Back to Top